Perfluoroalkyl substances are increased in patients with late-onset ulcerative colitis and induce intestinal barrier defects ex vivo in murine intestinal tissue

Abstract Background Environmental factors are strongly implicated in late-onset of inflammatory bowel disease. Here, we investigate whether high levels of perfluoroalkyl substances are associated with (1) late-onset inflammatory bowel disease, and (2) disturbances of the bile acid pool. We further explore the effect of the specific perfluoroalkyl substance perfluorooctanoic acid on intestinal barrier function in murine tissue. Methods Serum levels of perfluoroalkyl substances and bile acids were assessed by ultra-performance liquid chromatography coupled to a triple-quadrupole mass spectrometer in matched samples from patients with ulcerative colitis (n = 20) and Crohn’s disease (n = 20) diagnosed at the age of ≥55 years. Age and sex-matched blood donors (n = 20), were used as healthy controls. Ex vivo Ussing chamber experiments were performed to assess the effect of perfluorooctanoic acid on ileal and colonic murine tissue (n = 9). Results The total amount of perfluoroalkyl substances was significantly increased in patients with ulcerative colitis compared to healthy controls and patients with Crohn’s disease (p < .05). Ex vivo exposure to perfluorooctanoic acid induced a significantly altered ileal and colonic barrier function. The distribution of bile acids, as well as the correlation pattern between (1) perfluoroalkyl substances and (2) bile acids, differed between patient and control groups. Discussion Our results demonstrate that perfluoroalkyl substances levels are increased in patients with late-onset ulcerative colitis and may contribute to the disease by inducing a dysfunctional intestinal barrier.

[1]  Å. Keita,et al.  Colonic paracellular permeability and circulating zonulin-related proteins , 2021, Scandinavian journal of gastroenterology.

[2]  J. Irudayaraj,et al.  Effect of Perfluorooctanoic Acid on the Epigenetic and Tight Junction Genes of the Mouse Intestine , 2020, Toxics.

[3]  Å. Keita,et al.  The Intestinal Barrier and Current Techniques for the Assessment of Gut Permeability , 2020, Cells.

[4]  A. Braeuning,et al.  Impairment of bile acid metabolism by perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) in human HepaRG hepatoma cells , 2020, Archives of Toxicology.

[5]  M. Dubinsky,et al.  Association Between Early-life Exposures and Inflammatory Bowel Diseases, Based on Analyses of Deciduous Teeth. , 2020, Gastroenterology.

[6]  H. Sokol,et al.  Gut microbiota-derived metabolites as key actors in inflammatory bowel disease , 2020, Nature Reviews Gastroenterology & Hepatology.

[7]  David S. Wishart,et al.  Using MetaboAnalyst 4.0 for Comprehensive and Integrative Metabolomics Data Analysis , 2019, Current protocols in bioinformatics.

[8]  D. Philpott,et al.  Nod‐like receptors are critical for gut–brain axis signalling in mice , 2019, The Journal of physiology.

[9]  M. Orešič,et al.  Simultaneous determination of perfluoroalkyl substances and bile acids in human serum using ultra-high-performance liquid chromatography–tandem mass spectrometry , 2019, Analytical and Bioanalytical Chemistry.

[10]  T. Fletcher,et al.  Inflammatory bowel disease and biomarkers of gut inflammation and permeability in a community with high exposure to perfluoroalkyl substances through drinking water. , 2019, Environmental research.

[11]  P. Munkholm,et al.  Dietary risk factors for inflammatory bowel diseases in a high-risk population: Results from the Faroese IBD study , 2019, United European gastroenterology journal.

[12]  M. DeVito,et al.  Toxicokinetics of 8:2 fluorotelomer alcohol (8:2-FTOH) in male and female Hsd:Sprague Dawley SD rats after intravenous and gavage administration , 2019, Toxicology reports.

[13]  Å. Keita,et al.  Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease—Focusing on Intestinal Barrier Function , 2019, Cells.

[14]  David L. Smith,et al.  Biased efficacy estimates in phase-III dengue vaccine trials due to heterogeneous exposure and differential detectability of primary infections across trial arms , 2019, PloS one.

[15]  P. Gibson,et al.  Serum zonulin as a marker of intestinal mucosal barrier function: May not be what it seems , 2019, PloS one.

[16]  D. Greco,et al.  Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci , 2018, Inflammatory bowel diseases.

[17]  J. Allen,et al.  A Review of the Pathways of Human Exposure to Poly- and Perfluoroalkyl Substances (PFASs) and Present Understanding of Health Effects , 2018, Journal of Exposure Science & Environmental Epidemiology.

[18]  S. Kugathasan,et al.  PFOA and ulcerative colitis , 2018, Environmental research.

[19]  W. Alrefai,et al.  Pathophysiology of IBD associated diarrhea , 2018, Tissue barriers.

[20]  Jonas Halfvarson,et al.  Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden. , 2017, Gastroenterology.

[21]  J. Chiang Recent advances in understanding bile acid homeostasis , 2017, F1000Research.

[22]  George Michailidis,et al.  Sparse network modeling and metscape‐based visualization methods for the analysis of large‐scale metabolomics data , 2017, Bioinform..

[23]  Lisa M Bramer,et al.  Dynamics of the human gut microbiome in Inflammatory Bowel Disease , 2017, Nature Microbiology.

[24]  J. Forster,et al.  Na+/Taurocholate Cotransporting Polypeptide and Apical Sodium-Dependent Bile Acid Transporter Are Involved in the Disposition of Perfluoroalkyl Sulfonates in Humans and Rats. , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[25]  R. Baldassano,et al.  Diet in the pathogenesis and treatment of inflammatory bowel diseases. , 2015, Gastroenterology.

[26]  Ashwin N. Ananthakrishnan,et al.  Epidemiology and risk factors for IBD , 2015, Nature Reviews Gastroenterology &Hepatology.

[27]  M. D’Amato,et al.  Polymorphism in the Retinoic Acid Metabolizing Enzyme CYP26B1 and the Development of Crohn’s Disease , 2013, PloS one.

[28]  K. Steenland,et al.  Ulcerative Colitis and Perfluorooctanoic Acid (PFOA) in a Highly Exposed Population of Community Residents and Workers in the Mid-Ohio Valley , 2013, Environmental health perspectives.

[29]  A. Tjønneland,et al.  Association between Plasma PFOA and PFOS Levels and Total Cholesterol in a Middle-Aged Danish Population , 2013, PloS one.

[30]  P. Suñé,et al.  Positive Outcomes Influence the Rate and Time to Publication, but Not the Impact Factor of Publications of Clinical Trial Results , 2013, PloS one.

[31]  H. Sokol,et al.  Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases , 2012, Gut.

[32]  A. Lampen,et al.  Perfluorooctanoic acid affects the activity of the hepatocyte nuclear factor 4 alpha (HNF4α). , 2012, Toxicology letters.

[33]  J. M. Keller,et al.  Immunotoxicity of Perfluorinated Compounds: Recent Developments , 2012, Toxicologic pathology.

[34]  Y. Schneider,et al.  Dimethyl sulfoxide (DMSO) attenuates the inflammatory response in the in vitro intestinal Caco-2 cell model. , 2011, Toxicology letters.

[35]  M. V. van Erk,et al.  Perfluoroalkyl sulfonates cause alkyl chain length-dependent hepatic steatosis and hypolipidemia mainly by impairing lipoprotein production in APOE*3-Leiden CETP mice. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[36]  M. Lukáš,et al.  Bile acid malabsorption in inflammatory bowel disease: Assessment by serum markers , 2011, Inflammatory bowel diseases.

[37]  A. Öst,et al.  Low levels of bile acids increase bacterial uptake in colonic biopsies from patients with collagenous colitis in remission , 2011, Alimentary pharmacology & therapeutics.

[38]  J. Söderholm,et al.  Importance of disrupted intestinal barrier in inflammatory bowel diseases , 2011, Inflammatory bowel diseases.

[39]  S. Duncan,et al.  Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers , 2010, Gut.

[40]  Kyle Steenland,et al.  Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. , 2009, American journal of epidemiology.

[41]  T. Langmann,et al.  Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. , 2009, World journal of gastroenterology.

[42]  J. Chiang Hepatocyte nuclear factor 4α regulation of bile acid and drug metabolism , 2009, Expert opinion on drug metabolism & toxicology.

[43]  J. Chiang Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism. , 2009, Expert opinion on drug metabolism & toxicology.

[44]  K. Nagashima,et al.  Hepatocyte nuclear factor 4&agr; in the intestinal epithelial cells protects against inflammatory bowel disease , 2008, Inflammatory bowel diseases.

[45]  John W. Froehlich,et al.  Half-Life of Serum Elimination of Perfluorooctanesulfonate,Perfluorohexanesulfonate, and Perfluorooctanoate in Retired Fluorochemical Production Workers , 2007, Environmental health perspectives.

[46]  J. Söderholm,et al.  Dihydroxy bile acids increase mucosal permeability and bacterial uptake in human colon biopsies , 2007, Scandinavian journal of gastroenterology.

[47]  Robert C Buck,et al.  Absorption, distribution, metabolism, and elimination of 8-2 fluorotelomer alcohol in the rat. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[48]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[49]  Timothy J Wallington,et al.  Degradation of fluorotelomer alcohols: a likely atmospheric source of perfluorinated carboxylic acids. , 2004, Environmental science & technology.

[50]  J. Söderholm,et al.  Epithelia under metabolic stress perceive commensal bacteria as a threat. , 2004, The American journal of pathology.

[51]  Philippe Arnaud,et al.  Evaluation of the cytotoxicity effect of dimethyl sulfoxide (DMSO) on Caco2/TC7 colon tumor cell cultures. , 2002, Biological & pharmaceutical bulletin.

[52]  B. Strandvik,et al.  Serum bile acids in relation to disease activity and intake of dietary fibers in juvenile ulcerative colitis. , 1991, Digestion.

[53]  J. Lennard-jones,et al.  Classification of inflammatory bowel disease. , 1989, Scandinavian journal of gastroenterology. Supplement.

[54]  W. Roediger,et al.  Colonic bicarbonate output as a test of disease activity in ulcerative colitis. , 1984, Journal of clinical pathology.

[55]  R. I. Breuer,et al.  Comparison of the composition of faecal fluid in Crohn's disease and ulcerative colitis. , 1982, Gut.

[56]  F. Kern,et al.  Bile salt malabsorption in regional ileitis, ileal resection and mannitol-induced diarrhea. , 1968, The Journal of clinical investigation.